Biotech vet and ex-Biogen exec Tony Kingsley jumps to a new CEO post
More than six months after Tony Kingsley made an abrupt departure from the helm at Scholar Rock — and just a little more than a year after his arrival — we found out today what his next gig will be.
Kingsley is taking charge at Stablix, a biotech startup out of Versant that announced a $63 million launch raise just a couple of months before the biotech exec found the exit at Scholar Rock.
Stablix’s big idea revolves around stabilizing proteins where a short supply triggers disease by throwing a monkey wrench in the ubiquitination disposal system to retain functional, though imperfect, proteins. While Kingsley noted cystic fibrosis and some cancers as good examples of where the technology could be applied, he declined to comment on exactly which indications the roughly 20-person team will pursue first.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
